Herpes zoster

The European Commission ( EC ) has granted marketing authorization for Jyseleca ( Filgotinib 200 mg and 100 mg tablets...



Upadacitinib ( Rinvoq ) was developed as a JAK1-selective inhibitor by exploiting differences in the non-conserved domains outside the active...


Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2...


A meta-analysis of phase III, randomised, placebo-controlled trials has assessed the benefits and harms of Pregabalin ( Lyrica ) in...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death...


The European Commission has approved Empliciti ( Elotuzumab ) for the treatment of multiple myeloma as combination therapy with Revlimid...



The Committee of Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...


Anifrolumab is an investigational, fully human monoclonal antibody that binds to subunit 1 of the type I IFN receptor, inhibiting...


The FDA ( U.S. Food and Drug Administration ) has warned about reports of severe allergic reactions and herpes zoster...


Natalizumab ( Tysabri ), a humanized monoclonal antibody, was approved by the Food and Drug Administration ( FDA ) in...


Patients receiving Dimethyl fumarate ( DMF ) are at risk for opportunistic infections even without severe lymphocytopenia. An additional patient with...


Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more...


Herpes zoster is common and vaccine preventable. Stroke risk may be increased following zoster, but evidence is sparse and could...


The FDA ( Food and Drug Administration ) has approved Velcade ( Bortezomib ) for the retreatment of adult patients...


Mavrilimumab and Sifalimumab have met their primary endpoints in respective phase II studies, demonstrating further pipeline progress in core therapeutic...


Fingolimod ( Gilenya ) has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. The...


Tofacitinib ( Xeljanz ) is an oral Janus kinase ( JAK ) inhibitor for the treatment of rheumatoid arthritis (...